Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3850333 | 0.99 | KMT2A (0.57) | KMT2ACYP19A1NPC1TSHRHPGD | |
| SCHEMBL3846298 | 0.89 | KMT2A (0.52) | KMT2AHPGDMEN1MAPTKDM4E | |
| SCHEMBL6535502 | 0.84 | KMT2A (0.56) | KMT2AMEN1MAPTNPSR1HTT | |
| Bromide SCHEMBL3845852 | 0.82 | KMT2A (0.54) | KMT2ANPC1HPGDMEN1MAPT | |
| Alagebrium SCHEMBL1820212 | 0.80 | KMT2A (0.71) | KMT2ANPC1HPGDMEN1MAPT | |
| Bromide SCHEMBL3847549 | 0.80 | KMT2A (0.52) | KMT2AOPRM1OPRD1LMNAGAA | |
| Bromide SCHEMBL3845600 | 0.75 | KMT2A (0.76) | KMT2ANPC1MEN1MAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL3846894 | 0.74 | KMT2A (0.63) | KMT2AMEN1MAPTKDM4ECA12 | |
| Bromide SCHEMBL3854076 | 0.74 | KMT2A (0.71) | KMT2AHPGDMEN1MAPTSMN1; SMN2 | |
| Bromide SCHEMBL8078699 | 0.73 | KMT2A (0.58) | KMT2ANPC1TSHRHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257272-A4 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1257272-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020055527-A1 | Thiazolium compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-05-09 | — | — | US | claimed |
| WO-2001062250-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-08-30 | — | — | WO | claimed |
| EP-1257272-A4 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1257272-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6458819-B1 | INHIBITION OF FORMATION OF ADVANCED GLYCOSYLATION OF PROTEINS AND TO BREAKING THE CROSS-LINKS THAT FORM BETWEEN ADVANCED GLYCOSYLATION ENDPRODUCTS OR BETWEEN AGES AND OTHER PROTEINS. | ALTEON, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020055527-A1 | Thiazolium compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001062250-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055527-A1 | Thiazolium compounds and treatments of disorders associated with protein aging | TTR, RBP4, COL2A1 | KMT2A 4558/4885CYP19A1 4201/4885NPC1 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.